Why the study?
Does sacubitril-valsartan reduce mortality and morbidity in patients with systolic heart failure compared to enalapril?
Does sacubitril-valsartan reduce mortality and morbidity in patients with systolic heart failure compared to enalapril?
Sacubitril-valsartan is the first new drug in over a decade to decrease death rates in patients with systolic heart failure.
The PARADIGM-HF trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) found a combination drug containing sacubitril (a neprilysin inhibitor) and valsartan (an angiotensin II receptor blocker) superior to enalapril (an angiotensin-converting enzyme inhibitor) in patients with systolic heart failure. Recently approved by the US Food and Drug Administration, sacubitril-valsartan is the first new drug in over a decade to decrease death rates in patients with systolic heart failure.
No takes yet. Share an insight, caveat, or question.
Sabe et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: